Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

Integer Holdings Corporation (NYSE: ITGR) has announced a conference call to discuss its financial results and business highlights for the fourth quarter and full year ended December 31, 2025. The call is scheduled for Thursday, February 19, 2026, at 8 a.m. CT / 9 a.m. ET. It is an important event for investors, as Integer plans to issue a press release detailing its financial performance prior to the start of the call.

The conference call will cover not only the financial results but may also include forward-looking statements and other material information relevant to stakeholders. Investors can participate in the call via two dial-in numbers: (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. Those interested can join using Conference ID 3120125. Additionally, the call will be available as a live webcast and can also be accessed later via an archived replay on Integer's Investor Relations webpage.

For those who are unable to listen in live, an audio replay will be available for seven days after the call, ensuring that all interested parties can stay informed about the company's performance and strategic initiatives.

Integer Holdings Corporation is a prominent player in the medical device industry, specializing in contract development and manufacturing, particularly for cardiac rhythm management, neuromodulation, and vascular markets. The company is recognized for its commitment to quality and innovation, operating under well-known brands such as Greatbatch Medical® and Lake Region Medical®.

For more information about the call or to receive financial updates, investors are encouraged to visit Integer's website and subscribe to email alerts.

Integer Holdings Corporation (NYSE: ITGR) is set to host a conference call on February 19, 2026, to discuss its financial results for the fourth quarter and full year of 2025. This event is crucial for investors keen on evaluating the company's performance in the rapidly evolving medical device sector. With Integer positioning itself as a prominent contract development and manufacturing organization (CDMO), its performance metrics could provide key insights into broader market trends impacting the healthcare industry.

Investors should pay close attention not only to the financial figures but also to the commentary regarding market conditions and operational achievements. The company has established a reputation as a vital partner to OEMs and medical device companies, focusing on areas such as cardiac rhythm management and neuromodulation, which are critical for the aging population's healthcare needs. Q4 results are expected to shed light on any potential shifts in demand driven by technological advancements or regulatory changes that may impact Integer's operations.

Given Integer's commitment to innovation disclosed in its communications, analysts may glean insights into future product development and strategic initiatives. Any guidance provided during the call regarding revenue forecasts, R&D investment, or market expansion could significantly influence stock performance.

As the date approaches, short-term traders might want to position themselves based on market sentiment regarding Integer's brand strength and operational efficiency. Long-term investors should watch for indications of sustainable growth and competitive positioning, particularly in a sector characterized by rapid evolution and increasing competition. Keeping abreast of analyst ratings leading up to the call may further inform investment strategies. Ultimately, participating in the Q4 earnings call and reviewing the archived replay will be crucial for making informed investment decisions moving forward.